Supporting Public Health Laboratory Systems Research

Van Wave TW Scutchfield FD Honore PA . Recent advances in public health systems research in the United States. Annu Rev Public Health 2010; 31:283–95.

Baker EL Melton RJ Strange PV Fields ML Koplan JP Guerra FA Health reform and the health of the public. Forging community health partnerships. JAMA 1994; 272:1276–82.

McDade JE Hughes JM . The US needs a national laboratory system. US Med 1998; 34:9.

Skeels MR . Toward a national laboratory system for public health. Emerg Infect Dis 2001; 7(3 Suppl):531–2.

Witt-Kushner J Astles JR Ridderhof JC Martin RA Wilcke B Jr Downes FP Core functions and capabilities of state public health laboratories: a report of the Association of Public Health Laboratories. MMWR Recomm Rep 2002; 51(RR-14):1–8.

Valdiserri RO . Temples of the future: an historical overview of the laboratory's role in public health practice. Annu Rev Public Health 1993; 14:635–48.

Association of Public Health Laboratories. Laboratory System Improvement Program: promoting system improvement. Silver Spring (MD): APHL; 2008. Also available from: URL: http://www.aphl.org/aphlprograms/lss/performance/Pages/default.aspx [cited 2013 Apr 12].

Department of Health and Human Services (US). Healthy People 2020: improving the health of Americans [cited 2013 Apr 12]. Available from: URL: http://www.healthypeople.gov/2020/default.aspx

Updated guidelines for evaluating public health surveillance systems: recommendations from the Guidelines Working Group. MMWR Morb Mortal Wkly Rep 2001; 50(RR13):1–35.

Robinson AG Schroeder DM . The role of front-line ideas in Lean performance improvement. Qual Manag J 2009; 16:27–40.

Gradus MS Bhattacharyya S Murphy A Becker JN Baker BK . Milwaukee laboratory system improvement program (L-SIP). Public Health Rep 2013; 5(Suppl 2):xx–xx.

Vardakou I Pistos C Spillopoulou C . Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010; 197:157–62.

Seely KA Prather PL James LP Moran JH . Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 2011; 11:36–51.

Lapoint J James LP Moran CL Nelson LS Hoffman RS Moran JH . Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 2011; 49:760–4.

Brents LK Gallus-Zawada A Radominskka-Pandya A Vasiljevik T Prisinzano TE Fantegrossi WE Monohydrated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 2012; 83:952–61.

Dowdle WR . The future of the public health laboratory. Annu Rev Public Health 1993; 14:649–64.